Cancer cell apoptosis induction via cytolytic effector function (None)

"Cancer cell apoptosis induction via cytolytic effector function" refers broadly to the process whereby specialized immune cells—primarily CD8+ cytotoxic T lymphocytes and natural killer (NK) cells—recognize and kill malignant tumor cells by triggering programmed cell death (apoptosis). This involves the release of perforin/granzyme granules or engagement of death receptors on target cancer cells. The intrinsic apoptotic pathway includes mitochondrial outer membrane permeabilization leading to cytochrome c release, formation of the apoptosome complex activating caspase cascades culminating in controlled cellular destruction. Transcription factors like Krüppel-like factor 4 (KLF4) play critical roles in maintaining the differentiation state and functional capacity of these immune effectors. Enhancing this pathway through immunotherapies such as PD1 checkpoint blockade can improve anti-tumor immunity by restoring exhausted CD8+ T-cell functions. However, tumors often develop mechanisms that inhibit these processes, necessitating combination strategies targeting both tumor survival pathways and boosting host immunity for effective therapy[1][2][4][5]. In summary, "Cancer cell apoptosis induction via cytolytic effector function" should be understood as an important *immune-mediated biological mechanism* rather than a discrete molecular target suitable for direct drug binding. It encompasses multiple molecules including transcription factors like KLF4 regulating CTL differentiation/function, apoptotic proteins within tumor targets, and various signaling complexes involved in executing programmed cell death triggered by immune effectors.

Other names

Cytotoxic T lymphocyte-mediated apoptosisNK cell-mediated tumor cell killingImmune effector-induced cancer cell death

Drugs enhancing this pathway work by: Reinvigorating exhausted CD8+ T-cells to restore their cytolytic activity against tumor targets [2][4]; Promoting expression of transcription factors like KLF4 that drive differentiation into effective cytolytic transitory effector CD8+ T-cells [2][4]; Inducing intrinsic apoptotic pathways within cancer cells via mitochondrial cytochrome c release and caspase activation [1]; Blocking anti-apoptotic proteins such as Bcl-2/Bcl-xL to facilitate apoptosis [1].